[EN] MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS MACROCYCLIQUES DESTINÉS AU TRAITEMENT DE TROUBLES MÉDICAUX
申请人:ACHILLION PHARMACEUTICALS INC
公开号:WO2018160892A1
公开(公告)日:2018-09-07
Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
[EN] BENZO[B][1,8]NAPHTHYRIDINE ACETIC ACID DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS D'ACIDE ACÉTIQUE BENZO[B][1,8]NAPHTYRIDINE ET LEUR PROCÉDÉS D'UTILISATION
申请人:SILICON SWAT INC
公开号:WO2020232378A1
公开(公告)日:2020-11-19
Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided.
KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
申请人:AMGEN INC.
公开号:US20180177767A1
公开(公告)日:2018-06-28
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
申请人:Incyte Corporation
公开号:US20140200216A1
公开(公告)日:2014-07-17
The present disclosure describes bicyclic aromatic carboxamide derivatives, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
[EN] HETEROCYCLIC NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE NLRP3, DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
申请人:INNATE TUMOR IMMUNITY INC
公开号:WO2020150114A1
公开(公告)日:2020-07-23
The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).